For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
9
views
0
references
 Top references
cited by
48
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      0
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To investigate the efficacy and safety of gemcitabine and platinum salt, with or without trastuzumab, in patients with locally advanced or metastatic urothelial carcinoma overexpressing Her2.

          Related collections

          Author and article information

          Journal
          Journal ID (iso-abbrev): Eur. J. Cancer
          Title: European journal of cancer (Oxford, England : 1990)
          Publisher: Elsevier BV
          ISSN (Electronic): 1879-0852
          ISSN (Print): 0959-8049
          Publication date (Electronic): Jan 2015
          Volume: 51
          Issue: 1
          Affiliations
          [1 ] Department of Medical Oncology, Georges Pompidou Hospital, University Paris Descartes, Paris, France. Electronic address: stephane.oudard@egp.aphp.fr.
          [2 ] Department of Medical Oncology, Saint Louis Hospital, Paris, France.
          [3 ] Department of Medical Oncology, Georges Pompidou Hospital, University Paris Descartes, Paris, France.
          [4 ] Department of Medical Oncology, Cochin Hospital, Paris, France.
          [5 ] Department of Medical Oncology, Foch Hospital, Suresnes, France.
          [6 ] Department of Medical Oncology, Besançon University Hospital, Besançon, France.
          [7 ] Department of Medical Oncology, Victor Hugo Clinic, Le Mans, France.
          [8 ] Department of Oncology-Hematology, La Roche-Sur-Yon Hospital, La Roche-Sur-Yon, France.
          [9 ] Department of Medical Oncology, Saint Joseph Foundation, Paris, France.
          [10 ] Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France.
          [11 ] Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France.
          [12 ] Department of Oncology, Clinique Hartman, Neuilly-sur-Seine, France.
          [13 ] Department of Medical Oncology, Saint Luc University Clinics, Catholic University of Leuven (IREC/MIRO, pole ONCO), Brussels, Belgium.
          [14 ] Department of Medical Oncology, La Timone Hospital, Marseille, France.
          [15 ] Oncobiology Laboratory, René Huguenin Center, St Cloud, France.
          [16 ] Department of Oncology, Saint Perrin Hospital, Clermont Ferrand, France.
          [17 ] ARTIC Group (Association de Recherche sur les Thérapeutiques innovantes en Cancérologie), France.
          [18 ] Molecular Oncology, Curie Institute, UMR 144, CNRS, Paris, France.
          [19 ] Department of Medical Oncology, Curie Institute, Paris, France.
          Article
          Publisher Item ID: S0959-8049(14)01008-9
          DOI: 10.1016/j.ejca.2014.10.009
          PubMed ID: 25459391
          SO-VID: a665c39b-cae8-433a-9aea-11f4731d7850
          History

          Keywords: Advanced urothelial carcinoma,Gemcitabine,Her2 overexpression,Platinum salts,Trastuzumab
          Data availability:
          Keywords: Advanced urothelial carcinoma, Gemcitabine, Her2 overexpression, Platinum salts, Trastuzumab

          Comments

          Comment on this article